Alumis Inc. (NASDAQ: ALMS) is a Healthcare company (Biotechnology) with a market capitalization of $626M. The Maz Rating grades it against the other companies in its sector.
Alumis Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.84, Alumis Inc. trades at 84.5x sales and 1.6x book value. Over the last twelve months it generated about $7M of revenue and a net loss of $460M. It runs a gross margin of 88.0%, an operating margin of -6116.7% and a net margin of -5844.5%. It shows return on equity of -99.6%, return on invested capital of -106.4% and a free cash flow yield of -52.3%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 5.57. Over the past 52 weeks the share price ranged from $4.70 to $31.35, with a beta of -0.67.
Alumis Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 7 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.